VHL and kidney cancer: Belzutifan is FDA approved for the treatment of VHL-related kidney cancer, pancreatic neuroendocrine tumors, hemangioblastomas that do not need surgery right away, and advanced kidney cancer that has been previously treated with immunotherapy and antiangiogenic therapies such as cabozantinib or sunitinib.62,63 The MTD of belzutifan has not been determined.